Innovation1 Biotech (IVBT) Osake Kurssi

Innovation1 Biotech, Inc. is a drug discovery company, which engages in the development of modified Schedule 1 molecules of botanical origin to create derivatives for treatment of neurologic, psychiatric, dermatologic, and ophthalmologic disorders. The company is headquartered in Rockaway, New Jersey. The company went IPO on 2017-02-06. The company has a portfolio of products using five preclinical prodrugs, all fully synthetic without connection to botanical sourcing: a mushroom-derived psychedelic molecule for treatment of post-traumatic stress disorder and depression, a cannabinoid and tree bark derived psychedelic for treatment of addiction and three additional cannabinoid prodrugs addressing clinical indications of refractory pediatric epilepsy, hypertrophic scarring, and ocular inflammation. The first agent is a prodrug of psilocin, a molecule naturally found in certain mushroom species. The second agent is a prodrug of synthetic tetrahydrocannobivarin, a molecule naturally found in Cannabis that modulates the two principal cannabinoid receptors: CBR1 and CBR2. The third agent is a prodrug of synthetic cannabidophorol.